Snowdon, Inc., awarded contract for biowarfare countermeasures

Snowdon, Inc., has been awarded a three-year contract by the Department of Defense Program, Transformational Medical Technologies, for the preclinical development and discovery of new medical treatments to defeat biowarfare pathogens.

The Defense Threat Reduction Agency contract, worth up to $8.2 million, will support the project’s development. The contract will also support complementary Snowdon activities, including novel treatments for nervous system disorders, infectious diseases and pain.

For the project, Snowdon is partnering with two medical centers at the University of Medicine and Dentistry of New Jersey – New Jersey Medical School.

Dr. Nancy Connell, director of the Center for Emerging Pathogens in the department of medicine, will test drug candidates on particular biowarfare pathogens.

The Center is a strong candidate for this research because of its high-level biosafety containment facilities. Dr. David Perlin, director of the Public Health Research Institute, will assist Snowdon in the recently opened Regional Biocontainment Laboratory of UMDNJ.

Snowdon, Inc., was founded in 2007 by William J. Welsh. It specializes in developing and discovering small-molecule therapeutics to treat various conditions. Using its proprietary E-Prospector platform technology with expertise in computational drug design, chemistry and pharmacology, Snowdon is able to reduce the cost, time and risk of discovering new drugs.